Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.89 | N/A | +4.34% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.89 | N/A | +4.34% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management highlighted the positive EPS surprise as a sign of resilience. However, they did not provide specific revenue details or guidance.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They emphasized their commitment to long-term growth and innovation.
AbbVie's earnings report showed a positive EPS surprise, indicating better-than-expected profitability. However, the stock fell by 4.4%, likely due to the lack of revenue data and guidance, which left investors uncertain about future performance. This reaction suggests that while the EPS beat is a positive sign, the absence of comprehensive financial details may have raised concerns among investors.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AT&T INC
Jan 27, 2015